Diabetes in a warming world The Lancet Diabetes & Endocrinology ++... ++

Diabetes in a warming world The Lancet Diabetes & Endocrinology https://www.thelancet.com/journals/landia/article/PIIS2213-8587(26)00217-2/fulltext?dgcid=raven_jbs_etoc_email Oct 2026 Volume 14Number 10p793-866 https://www.thelancet.com/journals/landia/issue/vol14no10/PIIS2213-8587(26)X2008-3 Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial Prof Daisuke Yabe, MDa ∙ Toshihiko Shiraiwa, MDb ∙ Hiroyuki Ugai, MSc ∙ Dr Masakazu Takeuchi, PhDc Send email to takeuchi_masakazu@lilly.com ∙ Prof Ryo Suzuki, MD https://www.thelancet.com/journals/landia/article/PIIS2213-8587(26)00138-5/abstract?dgcid=raven_jbs_etoc_feature_landia Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial Prof Lixin Guo, MDa Send email to guolixin3234@bjhmoh.cn ∙ Xiaolei Bao, PhDb ∙ Prof Kuo-Chin Huang, MD PhDd ∙ Kristoffer Jensen Kolnes, MD PhDe ∙ Christian Laugesen, MD PhDe ∙ Yibing Lu, MDf ∙ et al. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(26)00133-6/abstract?dgcid=raven_jbs_etoc_feature_landia

Enhancing Clinical Understanding of Oral SERD-Based Therapies for Patients With ER-Positive/HER2-Negative MBC Authors: Nadia Harbeck, MD, PhD; Virginia Kaklamani, MD, DSc; Gregory Vidal, MD, PhD

https://www.medscape.org/viewarticle/enhancing-clinical-understanding-oral-serd-based-therapies-2026a1000a46?page=1&src=mkmcmr_driv_stan_mscpedu_260908-OUS-HONC-enhancing-clinical-understanding-oral-serd-based-therapies-2026a1000a46-cta&uac=148436CN

How to Help Manage Depression After GLP-1 Weight Regain Erica Lamberg

https://www.medscape.com/viewarticle/how-help-manage-depression-after-glp-1-weight-regain-2026a1000xan?ecd=WNL_trdalrt_pos1_ous_260909_etid8675509&uac=148436CN&impID=8675509 With more patients using GLP-1 weight-loss medications, physicians are increasingly seeing patients who discontinued therapy because of cost, limited pharmacy availability, intolerable adverse effects, or loss of insurance coverage.

Tenosynovial Giant Cell Tumor in Focus: Quickfire Insights From Multidisciplinary Experts Authors: Hans Gelderblom, MD, PhD; Michiel van de Sande, MD, PhD

https://www.medscape.org/viewarticle/tenosynovial-giant-cell-tumor-focus-quickfire-insights-2026a10006py?page=1&src=mkmcmr_driv_stan_mscpedu_260909-OUS-HONC-tenosynovial-giant-cell-tumor-focus-quickfire-insights-2026a10006py-cta&uac=148436CN

Read our latest conference content ++++ +++ Explore our content presented at ERS Congress 2026

ARTICLES Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial Free with registration https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01655-7/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_ers26&_hsenc=p2ANqtz-9XsYRBb0T_0ICIOJjh-RznGP81TYNtYrKDI-rOTxfUOTuBNxGkeo8A8BrBcRvMYoneC8-tfndUdHh3nirISwyBWbFDnQ&_hsmi=437945858&utm_content=437945858&utm_source=hs_email Cryobiopsy versus conventional bronchoscopic sampling for peripheral pulmonary lesions (Cryo-RCT): an open-label, parallel-group, randomised trial Free with registration until Sept 17th, 2026 https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00191-8/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_ers26&_hsenc=p2ANqtz--tnfkkQFT_LC8QXD5COgm4JZ4eyh5o_QwC4xzPF1YJ1Mox2vpZyvnw0CDv6lSP_J5qGaGdsqAiHO47qmxLB1pfdqIBjA&_hsmi=437945858&utm_content=437945858&utm_source=hs_email Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in children with cystic fibrosis aged 2–5 years (TIMBERLINE Trial VX21-121-105): a phase 3, open-label study Free with registration until Sept 17th, 2026 https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00257-2/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_ers26&_hsenc=p2ANqtz-_EjlieFJhIiDCnWzkwgYaYCpQsb2hei-EdTCVk9vbiYo0tQAWjZTc-RbN1apsdxFWJAZ_0I4LxQy07nrr3PKrueSrJHw&_hsmi=437945858&utm_content=437945858&utm_source=hs_email Global, regional, and national prevalence of second-hand smoke and attributable disease burden in 204 countries and territories, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 Open Access https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(26)00168-4/fulltext?dgcid=hubspot_email_conferencealerts_ers26&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-_cye-e0ydnBpRixMtqXhbWnsrCPzWGx5sUNH9mNc7fCEr6-zNpZ_NJJoqQg3Dwhv062iOPy9t5aiidiccyGDHA7bZfUw&_hsmi=437945858&utm_content=437945858&utm_source=hs_email SERIES The changing therapeutic landscape of small-cell lung cancer Free with registration https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01244-4/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_ers26&_hsenc=p2ANqtz-9l4htBAutdFpCfux9Fg6xQo2i6sJKPWy1MNZ3v3dLOSqgvIaSbOSn55JgT_hkrSQh5ySIcT7AB35EanmsY9bYmYK83Tg&_hsmi=437945858&utm_content=437945858&utm_source=hs_email Targeted therapies in advanced non-small-cell lung cancer: new biomarkers and treatment strategies Free with registration https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00253-5/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_ers26&_hsenc=p2ANqtz--AARarKR9JMTBR-I-8elbu2fwvSF-V3S3RhrcdWToSgwYYsJbhhKLM4PRSF68QSaRZ5-CQc_o-oz7Sb4UtiDsXBIpHVA&_hsmi=437945858&utm_content=437945858&utm_source=hs_email Early-stage non-small-cell lung cancer: emerging treatments and evolving challenges Open Access https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00221-3/fulltext?dgcid=hubspot_email_conferencealerts_ers26&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz--aP8eppIpfR-zEzT9CjEDUUETVDdgW0aL3NPiw8jiAzUybGoqIiixDj2bSPGwdmJSdi-cLJLjQsiHvn_R7ziZ78Ag4lg&_hsmi=437945858&utm_content=437945858&utm_source=hs_email

Funding news for global health researchers: September 7, 2026

Focus on HIV An estimated 40.9 million people globally are living with human immunodeficiency virus (HIV), first identified in the early 1980s. Remarkable scientific progress over four decades has led to the development of effective antiretroviral therapy (ART). In response to effective treatments and strategies, health care systems have begun to change; people living with HIV, once considered “too complex” for primary care, are returning to that setting. https://www.fic.nih.gov/?utm_source=funding-news&utm_medium=email&utm_campaign=funding-news

Beyond medical fit: redefining patient readiness in clinical trials 7 September 2026

https://rarerevolutionmagazine.com/beyond-medical-fit-redefining-patient-readiness-in-clinical-trials/ Clinical trials can offer a lifeline for rare disease patients, but the journey often demands more than just medical eligibility. trialport’s readifit™ tool looks to address this by empowering individuals to look beyond ‘medical fit’, evaluating their personal readiness and support networks to ensure they can stay the course, reducing dropouts through truly informed choices Written by Emma Bishop Interview with Dr Angelika Grechnaya, Ethan Graff-Radford, Lathe Ward and Charles Myrick, trialport With just 5% of rare diseases having an approved medicinal product1 a clinical trial can offer hope where there is none. However, there can be an assumption that this offer of hope means people will willingly take part and are able to do so. The impact of a clinical trial can bring unforeseen burdens and understanding these before consent is given is key. Dr Angelika Grechnaya is a counselling psychologist and has worked with trialport for the past eight months. She explains that medical fit is only the first gate to understanding whether someone is ready for a trial. The second stage is looking at whether someone can sustain participation. The decision goes from “Can I start?” to “Can I stay?” As Angelika explains, “To stay in a clinical trial is not one decision. You need to say multiple yeses. ‘Do I have enough time, enough money, enough support, is the trial aligned with what feels right for me, am I ok if the outcome is not what I expect?’” There are multiple factors that contribute to dropout rates: